De novo design of immunoglobulin-like domains. Read more about De novo design of immunoglobulin-like domains.
A Screening of Epigenetic Therapeutic Targets for Non-Small Cell Lung Cancer Reveals PADI4 and KDM6B as Promising Candidates. Read more about A Screening of Epigenetic Therapeutic Targets for Non-Small Cell Lung Cancer Reveals PADI4 and KDM6B as Promising Candidates.
PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma. Read more about PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.
The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use. Read more about The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use.
Discovery of Hit Compounds for Methyl-lysine Reader Proteins from a Target Class DNA-Encoded Library. Read more about Discovery of Hit Compounds for Methyl-lysine Reader Proteins from a Target Class DNA-Encoded Library.
Phosphorylation of the DNA repair scaffold SLX4 drives folding of the SAP domain and activation of the MUS81-EME1 endonuclease. Read more about Phosphorylation of the DNA repair scaffold SLX4 drives folding of the SAP domain and activation of the MUS81-EME1 endonuclease.
High-content live-cell multiplex screen for chemogenomic compound annotation based on nuclear morphology. Read more about High-content live-cell multiplex screen for chemogenomic compound annotation based on nuclear morphology.
Comparative structural analyses of the NHL domains from the human E3 ligase TRIM-NHL family. Read more about Comparative structural analyses of the NHL domains from the human E3 ligase TRIM-NHL family.
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19. Read more about Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C. Read more about Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C.
